Amgen Inc.
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Robert A. Bradway
- Full Time Employees
- 26,700
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- One Amgen Center Drive Thousand Oaks CA United States of America 91320-1799
- IPO Date
- Jun 17, 1983
- CIK
- 0000318154
- Website
- amgen.com
- Similar Companies
- Business
- Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Company News
Final Trades: John Deere, Copart, Amgen and the IYH
2 Biotech Stocks to Buy Hand Over Fist in October
The Art of Valuation: Discovering Amgen Inc's Intrinsic Value
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
3 Magnificent Dividend Stocks to Buy in October
Buy 2 October Dogs Of The Dow And Watch 5 More
Amgen (AMGN) Increases Yet Falls Behind Market: What Investors Need to Know
Alumis: Could This Broken Immunology IPO Become The Next Amgen?
Why Amgen (AMGN) Dipped More Than Broader Market Today
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE
Prescription For Dividends: Why Amgen Is More Than Just A Safe Bet
Amgen (AMGN) Ascends While Market Falls: Some Facts to Note
Federman & Sherwood Investigates Amgen, Inc. for Data Breach
Calls of the Day: Salesforce, Walmart, Pepsico and Amgen
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why
Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Amgen's stock falls 4% as analysts say drug updates lag competitors
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors